Image Parkinson’s Disease Progression Study
The purpose of this research study is to investigate how the brain and motor behavior changes Parkinson’s disease over time in response to rasagiline and to investigate new methods of evaluating non-invasive MRI-based biomarkers of PD progression in the brain. The drug rasagiline will be tested in this study.
Rasagiline has been prescribed by doctors for many years to treat symptomatic Parkinson’s disease. It is FDA approved for the treatment of Parkinson’s disease but has not been shown to slow disease progression.
- 2 testing days in Gainesville: baseline and after one year
- Testing days involve cognitive, motor, and MRI testing
- After first test, you will be placed into one of two groups and receive one year of either rasagiline or placebo
- All costs covered by study including medication (placebo or rasagiline), travel, hotel, and stipend
- Diagnosed with Parkinson’s disease within last 5 years
- 40-77 years old
For additional study information, please contact David Vaillancourt:
- (352) 294-1770
Study Information Flyer
Can be done from home
KeywordsParkinson disease, Parkinson's disease, Parkinson's disease - resources, Neurology
Principal InvestigatorDavid Vaillancourt, PhD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.